Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Open Access
- 29 October 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 5 (1), 1-19
- https://doi.org/10.1038/s41392-020-00348-8
Abstract
Recent studies have demonstrated the potential of natural killer (NK) cells in immunotherapy to treat multiple types of cancer. NK cells are innate lymphoid cells that play essential roles in tumor surveillance and control that efficiently kill the tumor and do not require the major histocompatibility complex. The discovery of the NK’s potential as a promising therapeutic target for cancer is a relief to oncologists as they face the challenge of increased chemo-resistant cancers. NK cells show great potential against solid and hematologic tumors and have progressively shown promise as a therapeutic target for cancer immunotherapy. The effector role of these cells is reliant on the balance of inhibitory and activating signals. Understanding the role of various immune checkpoint molecules in the exhaustion and impairment of NK cells when their inhibitory receptors are excessively expressed is particularly important in cancer immunotherapy studies and clinical implementation. Emerging immune checkpoint receptors and molecules have been found to mediate NK cell dysfunction in the tumor microenvironment; this has brought up the need to explore further additional NK cell-related immune checkpoints that may be exploited to enhance the immune response to refractory cancers. Accordingly, this review will focus on the recent findings concerning the roles of immune checkpoint molecules and receptors in the regulation of NK cell function, as well as their potential application in tumor immunotherapy.Keywords
This publication has 304 references indexed in Scilit:
- GMP-Compliant, Large-Scale Expanded Allogeneic Natural Killer Cells Have Potent Cytolytic Activity against Cancer Cells In Vitro and In VivoPLOS ONE, 2013
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicityBlood, 2012
- Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling PathwaysMolecular and Cellular Biology, 2011
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patientsBlood, 2011
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibodyBlood, 2010
- CD73: A Novel Target for Cancer ImmunotherapyCancer Research, 2010
- CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune SuppressionCancer Research, 2010
- The A2aR adenosine receptor controls cytokine production in iNKT cellsEuropean Journal of Immunology, 2010
- Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cellsBlood, 2009
- A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9Biochemical and Biophysical Research Communications, 2006